ESHAP方案治疗复发性或难治性非霍奇金淋巴瘤的临床观察  

A clinical observation of ESHAP regimen in the treatment of refractory or recurrent non-Hodgkin' s lymphoma

作　　者：牛占恩[1] 袁堂玲[1] 徐胜军[1] 李霞[1] 孙积峰[1] 张伟克[1] 

机构地区：[1]泰山医学院附属莱钢医院肿瘤血液科,山东莱芜271104

出　　处：《现代肿瘤医学》2009年第4期722-724,共3页Journal of Modern Oncology

摘　　要：目的:观察ESHAP方案治疗难治性或复发性非霍奇金淋巴瘤(NHL)的疗效及不良反应。方法:采用足叶乙甙、甲基强的松、顺铂、阿糖胞苷联合治疗20例NHL观察其治疗及不良反应。结果:20例中,完全缓解(CR)5例,部分缓解(PR)10例,总有效率(RR)75%。难治性6例中CR1例,PR3例,RR67%。复发性14例中CR4例,PR7例,RR79%。ESHAP方案的主要不良反应为骨髓抑制,白细胞减少的发生率为100%,Ⅲ-Ⅳ度为55%,血红蛋白及血小板减少的发生率分别为35%和55%,胃肠道反应发生率为45%,脱发发生率为55%,患者均可耐受。结论:ESHAP方案治疗复发性或难治性NHL是一种较理想的治疗方案。Objective： To observe the efficacy and the side effect of ESHAP in the treatment of refractory or recurrent Non -Hodgkin＇s lymphoma （NHL）. Methods： Using etoposide,methylprednwasolone, cisplatin and eytarabine to treat 20 eases of NHL. Results：Of the 20 eases ,5 eases had complete remission （CR） , 10 eases had partial remission （ PR）, and the total response rate （RR） was 75 %. Of the 6 refractory cases, 1 ease had CR, and 3 eases had PR. Of the 14 recurrent cases,4 eases had CR,7 eases had PR and the RR rate was 79%. The major side effect of the ESHAP regimen was bone marrow suppression, leukopenia rate was 100% , 55% of which were in grade Ⅲ and grade Ⅳ ,hemoglobin decrease rate and thrombocytopenia rate were 35% and 55% respectively, gastrointestinal reaction rate was 45%, and hair loss rate was 55 %, all were tolerable. Conclusion ：ESHAP regimen was ideal in the treatment of recurrent or refractory non - Hodgkin＇s lymphoma.

关 键 词：ESHAP 难治性或复发性 非霍奇金淋巴瘤 

分 类 号：R733.4[医药卫生—肿瘤]